Movement Alert｜Viking Therapeutics Rises 8.68% in Regular Trading, Phase 1 Clinical Trial of Novel Weight Loss Drug VK3019 Boosts Market Sentiment

Market Focus07-08

On July 8, Viking Therapeutics rose 8.68% in regular trading, trading at $42.11 per share, with turnover of $134 million. The rally was driven by the company's recent announcement that it has initiated a Phase 1 single ascending dose clinical trial of its investigational weight loss drug VK3019, following FDA clearance of the investigational new drug application.

VK3019 is a dual amylin and calcitonin receptor agonist. The trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of single subcutaneous injections of VK3019 in healthy adults with a body mass index of at least 30. This marks a new pipeline expansion beyond VK2735, the company's dual GLP-1/GIP receptor agonist whose Phase 2 results were published in the journal Obesity earlier this year.

Multiple advancing clinical programs, combined with an analyst consensus Buy rating and average price target of approximately $94.62, continue to underpin bullish sentiment toward Viking Therapeutics' obesity treatment portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135695407?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 03:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135695407","market":"us","top_or_hot":-1,"title":"Movement Alert｜Viking Therapeutics Rises 8.68% in Regular Trading, Phase 1 Clinical Trial of Novel Weight Loss Drug VK3019 Boosts Market Sentiment","media":"Market Focus","content":"<p><p>On July 8, Viking Therapeutics rose 8.68% in regular trading, trading at $42.11 per share, with turnover of $134 million. The rally was driven by the company's recent announcement that it has initiated a Phase 1 single ascending dose clinical trial of its investigational weight loss drug VK3019, following FDA clearance of the investigational new drug application.</p><p>VK3019 is a dual amylin and calcitonin receptor agonist. The trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of single subcutaneous injections of VK3019 in healthy adults with a body mass index of at least 30. This marks a new pipeline expansion beyond VK2735, the company's dual GLP-1/GIP receptor agonist whose Phase 2 results were published in the journal Obesity earlier this year.</p><p>Multiple advancing clinical programs, combined with an analyst consensus Buy rating and average price target of approximately $94.62, continue to underpin bullish sentiment toward Viking Therapeutics' obesity treatment portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Viking Therapeutics Rises 8.68% in Regular Trading, Phase 1 Clinical Trial of Novel Weight Loss Drug VK3019 Boosts Market Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Viking Therapeutics Rises 8.68% in Regular Trading, Phase 1 Clinical Trial of Novel Weight Loss Drug VK3019 Boosts Market Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-08 03:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 8, Viking Therapeutics rose 8.68% in regular trading, trading at $42.11 per share, with turnover of $134 million. The rally was driven by the company's recent announcement that it has initiated a Phase 1 single ascending dose clinical trial of its investigational weight loss drug VK3019, following FDA clearance of the investigational new drug application.</p><p>VK3019 is a dual amylin and calcitonin receptor agonist. The trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of single subcutaneous injections of VK3019 in healthy adults with a body mass index of at least 30. This marks a new pipeline expansion beyond VK2735, the company's dual GLP-1/GIP receptor agonist whose Phase 2 results were published in the journal Obesity earlier this year.</p><p>Multiple advancing clinical programs, combined with an analyst consensus Buy rating and average price target of approximately $94.62, continue to underpin bullish sentiment toward Viking Therapeutics' obesity treatment portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VKTX","symbol_name":"Viking Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1135695407","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135695407","pubTimestamp":1783452958,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 8, Viking Therapeutics rose 8.68% in regular trading, trading at $42.11 per share, with turnover of $134 million. The rally was driven by the company's recent announcement that it has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VKTX":"Viking Therapeutics, Inc."},"translate_title":"动静快讯|Viking Therapeutics常规交易涨8.68%新型减肥药VK3019 1期临床试验提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1},"content_text":"On July 8, Viking Therapeutics rose 8.68% in regular trading, trading at $42.11 per share, with turnover of $134 million. The rally was driven by the company's recent announcement that it has initiated a Phase 1 single ascending dose clinical trial of its investigational weight loss drug VK3019, following FDA clearance of the investigational new drug application.VK3019 is a dual amylin and calcitonin receptor agonist. The trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of single subcutaneous injections of VK3019 in healthy adults with a body mass index of at least 30. This marks a new pipeline expansion beyond VK2735, the company's dual GLP-1/GIP receptor agonist whose Phase 2 results were published in the journal Obesity earlier this year.Multiple advancing clinical programs, combined with an analyst consensus Buy rating and average price target of approximately $94.62, continue to underpin bullish sentiment toward Viking Therapeutics' obesity treatment portfolio.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135695407","isCrawlerRequest":true}